Sticking Point: Novartis Menveo Vaccine Faces Delay Over FDA Request For Info
This article was originally published in The Pink Sheet Daily
Executive Summary
Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.